Anatomic changes in the abdominal cavity during intraperitoneal chemotherapy: prospective study using scintigraphic peritoneography.
Twenty-one patients undergoing either adjuvant or palliative intraperitoneal (ip) chemotherapy had repeated scintigraphic peritoneographies. Significant scintigraphic ip changes were recorded in 11 patients (52%). In patients without residual disease at the time of ip chemotherapy, the rate of ip mal-distribution reached 70%. These alterations did not correlate with clinical complications. Our study suggested that, independently of clinical assessment, scintigraphic peritoneography is a useful test for identifying patients who are no longer suitable for ip treatment, due to inadequate locoregional distribution.
de Forni
M
M
Départment of Medical Oncology, Centre Claudius-Regaud, Toulouse, France.
Boneu
A
A
Otal
P
P
Martel
P
P
Shubinski
R
R
Bugat
R
R
Lucot
H
H
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010529:Peritoneal Cavity / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D013668:Technetium Tc 99m Aggregated Albumin / Q000493:pharmacokinetics; D014018:Tissue Distribution
D000970:Antineoplastic Agents; D013668:Technetium Tc 99m Aggregated Albumin